Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611692 | 0.83 | TSHR (0.58) | LMNAF2TDP1TSHRKMT2A | |
| SCHEMBL9318015 | 0.83 | LMNA (0.56) | LMNAF2TDP1TSHRKMT2A | |
| SCHEMBL3994318 | 0.81 | LMNA (0.54) | LMNAF2TDP1TSHRKMT2A | |
| SCHEMBL3994317 | 0.81 | LMNA (0.54) | LMNAF2TDP1TSHRKMT2A | |
| SCHEMBL27192192 | 0.81 | LMNA (0.54) | LMNAF2TDP1TSHRKMT2A | |
| SCHEMBL15485653 | 0.81 | LMNA (0.54) | PTPN1GSK3BLMNAF2TDP1 | |
| Water SCHEMBL21440321 | 0.81 | LMNA (0.54) | LMNAF2TDP1TSHRKMT2A | |
| SCHEMBL242716 | 0.81 | LMNA (0.57) | LMNAF2TDP1TSHRKMT2A | |
| SCHEMBL52413 | 0.79 | LMNA (0.70) | LMNAF2TDP1TSHRKMT2A | |
| Benzene SCHEMBL27793442 | 0.79 | LMNA (0.70) | LMNAF2TDP1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905258-B2 | 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases | SOUTHERN RESEARCH INSTITUTE (US) | 2024-02-20 | — | — | US | disclosed |
| CN-116761819-A | Compounds or salts thereof, and antibodies derived therefrom | 味之素株式会社 | 2023-09-15 | — | — | CN | disclosed |
| US-20230002331-A1 | 2-AMINOARYL-5-ARYLOXAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RES INST (US) | 2023-01-05 | — | — | US | disclosed |
| US-20210188791-A1 | 2-AMINOARYL-5-ARYLOXAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RESEARCH INSTITUTE | 2021-06-24 | — | — | US | disclosed |
| WO-2019164996-A1 | 2-AMINOARYL-5-ARYLOXAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RESEARCH INSTITUTE (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-08-04 | — | — | US | disclosed |
| EP-2270026-B1 | Compounds for proteasome enzyme inhibition | ONYX THERAPEUTICS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20150361134-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361134-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2015-12-17 | — | — | US | disclosed |
| EP-1224467-B1 | PROTECTING ALKYLATING REAGENTS USED FOR QUANTIFYING HOMOCYSTEINE | DADE BEHRING MARBURG GMBH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20040198703-A1 | Protecting groups for biological labeling | KECZER STEYE DE (US) | 2004-10-07 | — | — | US | disclosed |
| US-6783947-B1 | FOR DETECTING AMOUNT OF HOMOCYSTEINE IN SAMPLE; COMPRISES ALPHA-HALOKETONE AND DEPROTECTING AGENTS; FOR BIOASSAYS/CONJUGATION KITS | DADE BEHRING MARBURG GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
| EP-1224467-A2 | PROTECTING ALKYLATING REAGENTS USED FOR QUANTIFYING HOMOCYSTEINE | Dade Behring Marburg GmbH (DE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001018548-A2 | PROTECTING ALKYLATING REAGENTS USED FOR QUANTIFYING HOMOCYSTEINE | DADE BEHRING MARBURG GMBH (DE) | 2001-03-15 | — | — | WO | disclosed |
| CN-1089608-A | Imidazopyridine | MERCK PATENT GMBH (DE) | 1994-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905258-B2 | 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases | SMN1; SMN2, TDP2, NFKBIA | PTPN1 3784/4885GSK3B 191/4885LMNA 1183/4885 |
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | PTPN1 643/4885GSK3B 4157/4885LMNA 3083/4885 |
| US-20040034232-A1 | Amide derivative | HDAC2, ZC3HAV1, HDAC4 | PTPN1 1540/4885GSK3B 1084/4885LMNA 4369/4885 |
| US-20230002331-A1 | 2-AMINOARYL-5-ARYLOXAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, TDP2, NFKBIA | PTPN1 3784/4885GSK3B 191/4885LMNA 1183/4885 |
| US-20150361134-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | PTPN1 643/4885GSK3B 4157/4885LMNA 3083/4885 |
| US-20210188791-A1 | 2-AMINOARYL-5-ARYLOXAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, TDP2, NFKBIA | PTPN1 3784/4885GSK3B 191/4885LMNA 1183/4885 |
| US-20040198703-A1 | Protecting groups for biological labeling | MGMT, PTMS, BCKDK | PTPN1 4318/4885GSK3B 3509/4885LMNA 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.